These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28541985)

  • 21. Brodalumab (Siliq
    Gupta AK; Versteeg SV; Abramovits W; Vincent KD
    Skinmed; 2017; 15(4):281-285. PubMed ID: 28859739
    [No Abstract]   [Full Text] [Related]  

  • 22. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 23. [Personal experience with the use of infliximab].
    Carretero G
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():36-42. PubMed ID: 19080990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab: efficacy in psoriasis.
    Arsiwala S
    Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S25-34. PubMed ID: 23974692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience.
    Cannavò SP; Postorino E; Aragona E; Bartolotta A; Papaianni V; Guarneri C
    J Dermatolog Treat; 2018; 29(sup1):9-11. PubMed ID: 30247938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Patient education. Information letter on treatment of psoriasis with infliximab (Remicade)].
    Groupe de recherche sur psoriasis de Société française de dermatologie, mai 2011
    Ann Dermatol Venereol; 2011 Dec; 138(12):865-7. PubMed ID: 22137633
    [No Abstract]   [Full Text] [Related]  

  • 27. Biological agents in the treatment of psoriasis.
    Tzu J; Krulig E; Cardenas V; Kerdel FA
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Patient education. Information letter on treatment of psoriasis with ustekinumab (Stelara)].
    Groupe de recherche sur psoriasis de Société française de dermatologie, mai 2011
    Ann Dermatol Venereol; 2011 Dec; 138(12):874-5. PubMed ID: 22137636
    [No Abstract]   [Full Text] [Related]  

  • 29. [Ustekinumab].
    Ortonne JP
    Ann Dermatol Venereol; 2011 Dec; 138(12):848-50. PubMed ID: 22137626
    [No Abstract]   [Full Text] [Related]  

  • 30. The management of moderate-to-severe chronic plaque psoriasis.
    Tonini A; Panduri S; D' Erme AM; Papadia F; Romanelli M; Krueger JG; Chiricozzi A
    G Ital Dermatol Venereol; 2017 Oct; 152(5):447-457. PubMed ID: 28534602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agents.
    Sobell JM; Kalb RE; Weinberg JM
    J Drugs Dermatol; 2009 Mar; 8(3):230-8. PubMed ID: 19271369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab.
    Brunasso AM; Puntoni M; Delfino C; Massone C
    Eur J Dermatol; 2012; 22(1):133-5. PubMed ID: 22134100
    [No Abstract]   [Full Text] [Related]  

  • 33. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis.
    Lisby S; Gniadecki R
    Acta Derm Venereol; 2004; 84(3):247-8. PubMed ID: 15202853
    [No Abstract]   [Full Text] [Related]  

  • 34. Psoriasis options abound. Ongoing research on Enbrel and Raptiva supports their use in psoriasis treatment.
    Krueger GG
    Health News; 2004 Jan; 10(1):10-1. PubMed ID: 15002383
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
    Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
    JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate.
    Warren RB; Brown BC; Carmichael AJ; Griffiths CE
    Clin Exp Dermatol; 2009 Apr; 34(3):415-6. PubMed ID: 19120390
    [No Abstract]   [Full Text] [Related]  

  • 38. Guselkumab (Tremfya) for psoriasis.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):179-180. PubMed ID: 29125591
    [No Abstract]   [Full Text] [Related]  

  • 39. Injectable Drug Approved for Moderate-to-Severe Eczema.
    Aschenbrenner DS
    Am J Nurs; 2017 Jul; 117(7):23. PubMed ID: 28644285
    [No Abstract]   [Full Text] [Related]  

  • 40. A promising step forward in psoriasis therapy.
    Stern RS
    JAMA; 2003 Dec; 290(23):3133-5. PubMed ID: 14679277
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.